One-Year Results of a Phase I/II Randomized, Double-Masked, Placebo-Controlled Study of Processed Amniotic Fluid Drops After PRK

被引:2
|
作者
Kirschenbaum, Malka Davina [1 ]
Hu, Katherine S. [1 ]
Ip, Colin S. [1 ]
Lin, Amy [1 ]
Pierce, Jan [2 ]
Holubkov, Richard [3 ]
Jensen, Hailey [3 ]
Mifflin, Mark D. [1 ]
机构
[1] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA
[2] Univ Utah, Cell Therapy & Regenerat Med, Salt Lake City, UT USA
[3] Univ Utah, Dept Pediat, Salt Lake City, UT USA
关键词
amniotic fluid; PRK; refractive; laser; MEMBRANE TRANSPLANTATION; SUSPENSION; OUTCOMES; EYE;
D O I
10.1097/ICO.0000000000003474
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose:The aim of this study was to evaluate the 1-year outcomes of using processed amniotic fluid (pAF) postoperatively after photorefractive keratectomy (PRK).Methods:Sixty-one participants were randomized to receive either placebo or pAF drops. The drops were instilled 4 times daily for 1 week after PRK along with routine postoperative medications. The primary outcome measures included uncorrected visual acuity, topographic corneal irregularity measurement, and surface staining over 1 year.Results:A statistically significant difference in uncorrected distance visual acuity between the placebo and treatment groups was seen at 1 month post-PRK, with a visual advantage evident in the pAF group. A suggestive difference in corneal irregularity measurement was also seen between the placebo and treatment groups at 1 month postsurgery, with less irregularity noted in the pAF group. No differences in uncorrected distance visual acuity or corneal irregularity measurement were found at 3, 6, and 12 months. There was also no significant difference in corneal staining scores between the 2 groups at any of the measured time points.Conclusions:This 1-year study evaluating the safety and efficacy of pAF as an additional postoperative topical medication after PRK demonstrated that pAF offered a mild visual advantage at 1 month post-PRK. There were no late adverse events, and the intervention proved safe at 1 year.
引用
收藏
页码:955 / 960
页数:6
相关论文
共 50 条
  • [31] One-year results of golimumab compared with placebo in patients with active RA despite treatment with methotrexate: A phase II, randomized, double-blind, placebo-controlled, dose-ranging trial.
    Kay, J.
    Matteson, E. L.
    Dasgupta, B.
    Nash, P.
    Durez, P.
    Hall, S.
    Hsia, E. C.
    Chiruvolu, P.
    Han, J.
    Rahman, M. U.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S833 - S833
  • [32] A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease
    Taylor, Mike
    Ousler, George
    Torkildsen, Gail
    Walshe, Claire
    Fyfe, Matthew C. T.
    Rowley, Adele
    Webber, Steve
    Sheppard, John D.
    Duggal, Ajay
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 261 - 275
  • [33] Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol - A double-masked, randomized, one-year study
    Lass, JH
    Eriksson, GL
    Osterling, L
    Simpson, CV
    OPHTHALMOLOGY, 2001, 108 (02) : 264 - 271
  • [34] A one-year, randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis: Results of the FLIRT pilot trial
    Ratziu, V.
    Jacqueminet, S.
    Giral, P.
    Podevin, P.
    Serfaty, L.
    Charlotte, F.
    Bruckert, E.
    Bernhardt, C.
    Grimaldi, A.
    Poynard, T.
    DIABETOLOGIA, 2006, 49 : 704 - 705
  • [35] Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: A randomized, double-masked, placebo-controlled trial
    Price, FW
    Price, MO
    Zeh, W
    Dobbins, K
    JOURNAL OF REFRACTIVE SURGERY, 2002, 18 (02) : 140 - 144
  • [36] One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
    N Finer
    WPT James
    PG Kopelman
    MEJ Lean
    G Williams
    International Journal of Obesity, 2000, 24 : 306 - 313
  • [37] One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
    Finer, N
    James, WPT
    Kopelman, PG
    Lean, MEJ
    Williams, G
    INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (03) : 306 - 313
  • [38] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [39] IMMUNOLOGICAL CHANGES AFTER IMMUNOTHERAPY IN ASTHMATIC-CHILDREN - A ONE-YEAR PLACEBO-CONTROLLED STUDY
    HSIEH, KH
    WANG, SY
    LIN, KL
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1992, 89 (01) : 323 - 323
  • [40] Myopia Control with Low-Dose Atropine in European Children: Six-Month Results from a Randomized, Double-Masked, Placebo-Controlled, Multicenter Study
    Hvid-Hansen, Anders
    Jacobsen, Nina
    Moller, Flemming
    Bek, Toke
    Ozenne, Brice
    Kessel, Line
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (02):